CVE:HEM Hemostemix (HEM) Stock Price, News & Analysis C$0.14 -0.01 (-6.90%) As of 07/8/2025 12:16 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesInsider TradesBuy This Stock About Hemostemix Stock (CVE:HEM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hemostemix alerts:Sign Up Key Stats Today's RangeC$0.14▼C$0.1550-Day RangeC$0.08▼C$0.1552-Week RangeC$0.04▼C$0.43Volume313,700 shsAverage Volume409,782 shsMarket CapitalizationC$19.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada. Read More Receive HEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter. Email Address HEM Stock News HeadlinesHemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial - Seeking AlphaJuly 5, 2025 | seekingalpha.comHemostemix Closes $469,366 Private PlacementJuly 4, 2025 | finance.yahoo.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.July 9 at 2:00 AM | American Alternative (Ad)Hemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments! - Seeking AlphaJuly 3, 2025 | seekingalpha.comHemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!July 3, 2025 | finance.yahoo.comShares of Micro Cap Biotech Jump as New Law Opens Florida to Company’s Stem Cell TreatmentsJuly 3, 2025 | msn.comCroom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health LaunchJune 27, 2025 | finance.yahoo.comHemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible DebentureJune 26, 2025 | finance.yahoo.comSee More Headlines HEM Stock Analysis - Frequently Asked Questions How have HEM shares performed this year? Hemostemix's stock was trading at C$0.12 on January 1st, 2025. Since then, HEM shares have increased by 12.5% and is now trading at C$0.14. How do I buy shares of Hemostemix? Shares of HEM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Hemostemix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), Golden Share Resources (GSH), Nuvilex (PMCB), Algernon Pharmaceuticals (AGNPF), Defense Metals (DFMTF) and NIO (NIO). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:HEM CIKN/A Webwww.hemostemix.com Phone+1-403-3409207FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$5.00 million Net MarginsN/A Pretax MarginN/A Return on Equity37.07% Return on Assets-349.24% Debt Debt-to-Equity Ratio-55.07 Current Ratio0.04 Quick Ratio0.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.01 per share Price / Cash Flow10.77 Book ValueC($0.10) per share Price / Book-1.36Miscellaneous Outstanding Shares145,727,000Free FloatN/AMarket CapC$19.67 million OptionableNot Optionable Beta0.20 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (CVE:HEM) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemostemix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemostemix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.